Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b open-label intravenous blinatumomab study in Japanese adults with newly diagnosed Philadelphia-negative B-precursor acute lymphoblastic leukemia
jRCT2021240043Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoints: Number of participants with treatment-emergent adverse events, serious treatment-emergent adverse events, and treatment-related treatment-emergent adverse events and Number of participants experiencing adverse events of interest. Started Jan 2025; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2021240043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240043.